How long is a course of treatment with giritinib/segatan?

As an oral targeted drug, the length of time Gilteritinib/Segatan is used in acute myeloid leukemia (AML) does not have a clear and fixed course of treatment like traditional chemotherapy. Many patients will ask before taking medicine: How long does a course of treatment take? According to the data, the administration mode of gilitinib is usually continuous and regular daily oral administration, rather than a staged short-term course of treatment.

The treatment concept of giritinib is closer to that of antiviral drugs or chronic disease management drugs, that is, through long-term maintenance of the inhibition of FLT3 mutation signal, it can control the disease and delay recurrence. For patients with relapsed or refractory AML, it is generally recommended to take it continuously for at least several months before the effect can be evaluated, because the drug needs time to act on the differentiation and apoptosis processes of tumor cells. Some studies have shown that patients who take treatment for more than 6 months are more likely to achieve a durable response, but whether the treatment needs to be stopped depends on the control of the disease. If a patient achieves complete remission during treatment, the doctor may evaluate whether to continue maintenance therapy to reduce the risk of recurrence. If the disease is stable but the patient is ready for a hematopoietic stem cell transplant, giritinib can be used as bridging therapy until a transplant regimen is initiated.

From a safety perspective, as long as patients can tolerate it and there are no serious side effects, the course of giritinib can be continued for a long time. In other words, it is not a model of "stopping medication after a fixed course of treatment", but a strategy of "individualized treatment course". Therefore, patients should not simply understand a standardized treatment cycle, but should maintain communication with their doctors and determine the length of treatment through regular examinations and efficacy evaluation. With the deepening of research, there may be more precise treatment recommendations in the future, but currently giritinib emphasizes continuous treatment and dynamic adjustment rather than a simple staged treatment concept.

Reference materials:https://www.xospata.com/